Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Inclusion Criteria

• •All patients must have a diagnosis of chronic lymphocytic leukemia (CLL) by immunophenotyping and flow cytometry analysis of blood or bone marrow
• •* Patients must meet criteria for treatment based on the criteria proposed by National Cancer Institute (NCI)-sponsored CLL Working Group to include at least one of the following:
• •* Weight loss of more than 10% over the preceding 6 months; or
• •* Extreme fatigue attributable to progressive disease; or
• •* Fever or night sweats without evidence of infection; or
• •* Worsening anemia (Rai stage Ill) or thrombocytopenia (Rai stage IV); or
• •* Massive lymphadenopathy (\> 10 cm) or rapidly progressive lymphocytosis (lymphocyte doubling time \< 6 months); or
• •* Prolymphocytic or Richter's transformation; or
• •* Patients with CLL who have received at least one prior line of therapy; or
• •* Patients with CLL who have frequent infections and/or recurrent secondary cancers
• •No active central nervous system (CNS) disease
• •All patients must have a Karnofsky performance score \> 60%
• •Calculated creatinine clearance (by Cockcroft-Gault) of \> 50 ml/min
• •Patients must not have untreated or uncontrolled life-threatening infection
• •Patients must sign informed consent